Whitehead Connects presents Katrine Bosley

Katrine Bosley

Katrine Bosley, Chief Executive Officer, Editas Medicine

“25 Years in Biotech”

December 2, 2015
5:30 presentation; 6:30 networking reception
Whitehead Institute
Nine Cambridge Center
Cambridge, MA 02142

 

RSVP Now →

 

About Katrine Bosley
Katrine Bosley is the Chief Executive Officer of Editas Medicine. Katrine was recently the Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and prior to that, she was the CEO of Avila Therapeutics (acquired by Celgene). She was VP, Business Development at Adnexus Therapeutics and then VP, Strategic Operations after Adnexus’ acquisition by Bristol-Myers Squibb. Earlier, Katrine held several positions at Biogen in business development, commercial operations, and portfolio strategy and was part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University. In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a Board member of Galapagos NV (EURONEXT and NASDAQ: GLPG), of Scholar Rock, LLC, and of BIO – the Biotechnology Innovation Organization – and she is a review committee member for the Translation Fund of the Wellcome Trust.

About Whitehead Connects
Whitehead Connects is an initiative that brings renowned biology and biotech leaders to Whitehead Institute for an engaging presentation and dynamic networking opportunity for participants. Following the free, public lecture participants will have the opportunity to meet Whitehead postdoctoral fellows and learn about their latest discoveries.